Posted by Michael Wonder on 22 Sep 2025
Tremfya (guselkumab) achieves US approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen
19 September 2025 - Johnson & Johnson is initiating a head to head study seeking to demonstrate the superiority of Tremfya versus Skyrizi (risankizumab) in Crohn's disease, based on the confidence in the clinical profile.
Johnson & Johnson today announced that the US FDA has approved a subcutaneous induction regimen of Tremfya (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis.
